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of how technologies are chosen is essential. The decision criteria and its weights should 
represent the management’s as well as the potential user’s perspective of the technol-
ogy. METHODS: To identify relevant criteria in terms of technology acquisition, a 
literature review was carried out. As a second step 221 HTA-experts were confronted 
with the ten most frequent criteria, with the task to evaluate their importance and to 
supplement them. To evaluate the individual weight of each criterion a survey was 
conducted, including three relevant user groups within the sector of radiooncology. 
For each of the 115 recipients and an overall preference proﬁle was calculated using 
an AHP-model. The inﬂuence of factors such as job, leadership, sex, user, size of 
hospital and typ of hospital were also analyzed using an analysis of variance. 
RESULTS: As result of step one and two the following seven criteria were identiﬁed: 
effectiveness, the need for treatment, patient preferences, usability, cost-effectiveness, 
organizational impact, budget impact. The overall AHP-model identiﬁed the organi-
zational impact (16.9%) as the most relevant criterion, followed by the budget impact 
(15.7%). The variance analysis showed that all factors, except the size of the hospital 
inﬂuence certain criteria of the preference proﬁle in a signiﬁcant way. CONCLU-
SIONS: Surprisingly, the organizational impact is the most important criterion directly 
followed by the budget impact. The organizational impact is today often underesti-
mated. Therefore, organizational barriers exist and can delay or hinder innovation. 
To determine essential characteristics of a new technology and to lower barriers 
regarding its acceptance, the preferences of each group should be evaluated and 
integrated in decisions.
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OBJECTIVES: The purpose of this study is to better understand the types of evidence 
considered and how evidence is used by health care payers and payer intermediary 
organizations to evaluate prescription drugs and biologics for possible formulary 
inclusion. METHODS: We conducted semi-structured one-hour telephone interviews 
with key decision makers at payers and payer intermediary organizations. Respon-
dents included medical and pharmacy directors who actively participate in pharma-
ceutical technology assessment (PTA). Participants were asked to describe their PTA 
process and to rate the importance of the sources and types of evidence they review. 
RESULTS: Pharmacy and medical directors from 15 national and regional health 
plans, prescription drug plans, and pharmacy beneﬁt managers rated information used 
for PTA on a scale of 1 (not important) to 5 (very important). While preliminary 
results indicate that respondents rated peer-reviewed studies as the most important 
source of information (mean = 4.7), technology assessments such as comparative 
effectiveness studies (e.g., from AHRQ or Hayes) and internal (health plan) data on 
utilization were rated almost as highly (4.2 and 4.1, respectively). Medical directors 
gave comparative effectiveness studies higher ratings than did pharmacy directors (4.7 
vs. 3.8; p < 0.001). Among types of evidence, randomized control trials (RCTs) were 
rated the highest (mean = 4.6); budget impact analyses (mean = 3.1) and pharmaco-
economic studies (mean = 2.9) had substantially lower rating, although both of these 
received higher ratings from pharmacy vs. medical directors. There was little variation 
in ratings by payer type. CONCLUSIONS: While it is not surprising that key decision 
makers highly value RCTs from peer-review literature, other sources of information 
were rated as having essentially the same importance. Medical and pharmacy directors 
have signiﬁcant differences in the importance assigned to certain information. Addi-
tional data will help to explore variations in perceived value of information among 
different types of PTA staff and potentially differences across payer types.
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OBJECTIVES: Consultative Council (CC) is an independent body playing a central 
role in decision making of Polish Heath Technology Assessment Agency (AHTAPol). 
We were interested in how much safety issues of the appraised technologies concern 
members of CC and what is the inﬂuence of safety issues on CC’s decisions. 
METHODS: We analyzed decisions of CC published until the end of 2009 and dis-
tinguish those where safety issues were signiﬁcant arguments for decline. We indentify 
the type of key documents quotabled in the decisions in order confront them with 
documents included in manufacturer’s HTA reports. RESULTS: Among 148 CC’s 
decisions analyzed, 70 were negative and in 22 safety issues were signiﬁcant arguments 
against the positive recommendation (31% of all negative decisions). Apart of the 
manufacturer’s HTA reports, CC based mainly on EMEA or national Summary Of 
Product Characteristics (91%), FDA reports and Cochrane reviews (23% each), RCT 
not included in the submission (17%) and non-systematic reviews (13%). Manufac-
turer’s HTA reports on safety included mainly III phase RCTs (77%), II phase RCTs 
(36%), observational studies (27%), systematic (non-Cochrane) or non-systematic 
reviews (9%). Seldom, if ever, submitted reports mentioned FDA or EMEA reports 
and patient registries (5%). CONCLUSIONS: Safety issues were important argument 
in negative opinions of CC. Unlike efﬁcacy, safety analysis comprise evidence other 
than III phase RCTs. Manufacturer’s HTA reports did not cover many documents 
signiﬁcant to CC regarding safety. A wider safety analysis according to the ATHAPol’s 
guidelines 2009 would be required.
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OBJECTIVES: Drugs receive priority (P) or standard (S) review based on FDA’s 
perceptions that the drug offers signiﬁcant beneﬁt over existing options. The study 
will describe patient characteristics associated with drugs that got P and S approval. 
METHODS: This pilot study employed a retrospective cohort design using MEPS data 
(full year consolidated, prescription medicine, and medical condition ﬁles) from 
2004–2007. Subjects were identiﬁed from the prescription medicine ﬁles if they 
received P drugs (atorvastatin, pioglitazone, rosiglitazone, repaglinide) or S drugs 
(simvastatin, pravastatin, rosuvastatin, glimepiride, exenatide, sitagliptin). All other 
drugs that were received by these subjects and approved 1990 onwards were coded 
for their approval status from the FDA website. Subjects in the S group receiving any 
P drug or who received the aforementioned drugs from both groups were excluded. 
Variables at the year subjects entered the MEPS were analyzed. RESULTS: A total of 
5835 patients—3810 patients on one or more P drugs and 2025 on S drugs—were 
identiﬁed. There was no signiﬁcant difference of age of the patients in these groups. 
Patients’ race and gender (Asian vs. White OR = 1.556; female vs. male OR = 1.367) 
was associated (p < 0.05) with odds of receiving priority drugs. Patients receiving P 
drugs had signiﬁcantly (p < 0.05) higher number of comorbidities compared to those 
in the S group. Respiratory diseases, endocrine disorders, tumor, hypertension, and 
number of comorbidities were signiﬁcant (p < 0.05) predictors of receiving P drugs. 
Patients in the P group reported signiﬁcantly (p < 0.05) poorer health status. However, 
when adjusted with propensity score such difference was not associated with the drug 
categories. CONCLUSIONS: Patient demographics was associated with receiving 
antidiabetic and anticholesterol therapeutic classes of drugs that received priority 
review. After controlling for comorbidities, number of comorbidities was positively 
associated with likelihood of receiving P drugs. When adjusted for covariates, such 
categorization was not associated with self-reported health status.
HEALTH CARE USE & POLICY STUDIES – Prescribing Behavior  
& Treatment Guidelines
PHP91
DRUGS PRESCRIBING INDICATORS IN SECOND AND THIRD-LEVEL 
COMPLEXITY HOSPITALS FROM COLOMBIA
Buendia Rodriguez JA, Garcia Vega OA
Universidad Nacional de Colombia, Bogota, Colombia
OBJECTIVES: To evaluate drugs prescribing indicators of outpatient medication in 
medium- and high-level complexity hospitals from Colombia METHODS: This was 
a cross-sectional study where medication prescription was evaluated in 331 second- 
and third-level complexity hospitals from 27 Colombian departments during 2006–
2007 RESULTS: 38863 prescriptions for 3663 patients were analyzed; 54.7% of them 
patients afﬁliated to contributory health care system. Average prescribed medication 
per person was 2,2 (2,1–2,2 95 % CI), the percentage of antibiotics formulated by 
prescription was 29,2 % (28,7–29,6 95 % CI), essential prescribed medicines 
accounted for 64,2 % (63,7–64,6 95 % CI) and injectable medicines was 22,1 % 
(21,7–25,5 %). More than half the medications (62,1 %; 61,5–62,7 95 % CI) were 
in three ATC groups (anti-infectious agents, immunomodulating agents and medica-
tions for the alimentary and metabolic tract). DU90% consisted of 64 medications 
and the medication consumption was of 8, 39 daily deﬁned doses (DDD)/1000 patients 
CONCLUSIONS: Respect to previous studies in Colombia the indicators remain with 
few change, except the percentage of antibiotics formulated by prescription that 
increased more than recommended by OMS (25%). This is the ﬁrst report of DU90% 
and DDD in Colombian patients and these indicators must be continuously evaluated 
in future to follow the quality of prescription and drug consumption.
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OBJECTIVES: To evaluate the knowledge change among medical, pharmacy, and 
nurse practitioner students after attending a drug-drug interaction (DDI) educational 
program. METHODS: Students were given a DDI knowledge assessment containing 
15 drug pairs. They were asked to assess each drug pair and select the corresponding 
appropriate management strategy. Following the knowledge assessment, students 
attended a 45-minute training program during which all 15 drug pairs were addressed. 
The ﬁrst outcome of interest was “Management Strategy,” where students were given 
credit only if they selected the correct management strategy. Actions included “Avoid 
